Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745133 · ClinicalTrials.gov registry record · Phase 4
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Leon Kircik, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01745133: Completed Phase 4 study of Psoriasis, sponsored by Leon Kircik, M.D..
NCT01745133 is a Phase 4 study of Psoriasis that has completed, run by Leon Kircik, M.D.. The registered enrollment target is 63 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01745133, a Phase 4 study of Psoriasis, has completed, sponsored by Leon Kircik, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis. OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formulation. SORILUX Foam is a foam formulation of calcipotriene. Both medications have been approved by the FDA for treating plaque psoriasis.
Primary Outcome
Percentage of participants with clear or almost clear skin on the PGA scale. 0 = clear 1. = almost clear 2. = mild 3. = moderate 4. = severe
Conditions Studied
Interventions
- DRUG vehicle foam
- DRUG calcipotriene
- DRUG calcipotriene + clobetasol propionate
Study Locations (1)
Kentucky
- DermResearch, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
What the finished NCT01745133 record still lists
NCT01745133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which vehicle foam is the first listed.
NCT01745133 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT01745133 about?
NCT01745133 is a clinical study titled "Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis". The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis. OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formul...
What is the current status of trial NCT01745133?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2013-01. Estimated completion is 2014-08.
What conditions does trial NCT01745133 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01745133?
The interventions under investigation include: vehicle foam (DRUG), calcipotriene (DRUG), calcipotriene + clobetasol propionate (DRUG).
Who is sponsoring clinical trial NCT01745133?
This trial is sponsored by Leon Kircik, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01745133 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01745133's enrollment target sits among peer trials
63 69th of 125 higher than 57 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia